WST
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc historical holders
total: 4
Durable Capital Partners West Pharmaceutical Services Inc transactions over time
- Total transactions:
- 22
- New positions:
- 1
- Sold out:
- 1
- Added:
- 9
- Reduced:
- 11
- Held since:
- 2020 Q1
- Held for:
- 23 quarters
- Latest activity:
- 2025 Q4
Henry Ellenbogen has been an institutional investor in West Pharmaceutical Services Inc (WST) since 2020 Q1. According to 2026 Q1 report, Henry Ellenbogen doesn't hold any shares. The fund/company first acquired WST in 2020 Q1, initially purchasing 942,821 shares. Since the initial investment, Durable Capital Partners has made 21 more transactions in this position.
When did Henry Ellenbogen exit their WST position?
Henry Ellenbogen no longer holds West Pharmaceutical Services Inc (WST). They sold off their entire position in 2025 Q4, closing out an investment that began in 2020 Q1.
When did Henry Ellenbogen first invest in WST?
Henry Ellenbogen first invested in West Pharmaceutical Services Inc (WST) in 2020 Q1 at the reported quarter-end price of $152.25 per share, acquiring 942,821 shares in their initial purchase.
What is Henry Ellenbogen's average cost basis for WST?
Based on historical transaction data, Henry Ellenbogen's estimated cost basis for West Pharmaceutical Services Inc (WST) is approximately $219.80 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $219.80
- Weighted AVG sell price:
- $286.20
WST transactions history by Durable Capital Partners
22 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q4
|
0.00%
|
0
|
$262.33
|
|
-100% (-1,172,583)
|
-2.28%
|
|
2025 Q3
|
2.28%
|
1,172,583
|
$262.33
|
$307,603,698
|
+12.68% (+131,935)
|
+0.26%
|
|
2025 Q2
|
1.72%
|
1,040,648
|
$218.80
|
$227,693,782
|
-33.85% (-532,471)
|
-1.04%
|
|
2025 Q1
|
3.15%
|
1,573,119
|
$223.88
|
$352,189,882
|
+146.80% (+935,721)
|
+1.87%
|
|
2024 Q4
|
1.70%
|
637,398
|
$327.56
|
$208,786,089
|
-41.30% (-448,521)
|
-1.07%
|
|
2024 Q3
|
2.38%
|
1,085,919
|
$300.16
|
$325,949,447
|
+4.36% (+45,395)
|
+0.1%
|
|
2024 Q2
|
2.81%
|
1,040,524
|
$329.39
|
$342,738,200
|
+0.92% (+9,471)
|
+0.03%
|
|
2024 Q1
|
3.16%
|
1,031,053
|
$395.71
|
$407,997,983
|
-9.46% (-107,677)
|
-0.34%
|
|
2023 Q4
|
3.17%
|
1,138,730
|
$352.12
|
$400,969,608
|
-5.27% (-63,339)
|
-0.2%
|
|
2023 Q3
|
4.12%
|
1,202,069
|
$375.21
|
$451,028,309
|
-5.98% (-76,506)
|
-0.25%
|
|
2023 Q2
|
4.29%
|
$382.47
|
+2.96% (+36,757)
|
|||
|
2023 Q1
|
4.04%
|
$346.47
|
+11.51% (+128,134)
|
|||
|
2022 Q4
|
2.72%
|
$235.35
|
-5.58% (-65,763)
|
|||
|
2022 Q3
|
3.19%
|
$246.08
|
+18.65% (+185,411)
|
|||
|
2022 Q2
|
3.45%
|
$302.37
|
+32.83% (+245,705)
|
|||
|
2022 Q1
|
2.70%
|
$410.71
|
-12.90% (-110,879)
|
|||
|
2021 Q3
|
2.76%
|
$424.54
|
-9.68% (-92,053)
|
|||
|
2021 Q2
|
2.52%
|
$359.10
|
-1.79% (-17,362)
|
|||
|
2020 Q4
|
2.44%
|
$283.31
|
-12.43% (-137,493)
|
|||
|
2020 Q3
|
3.35%
|
$274.90
|
-10.88% (-135,073)
|
|||
|
2020 Q2
|
3.51%
|
$227.17
|
+31.65% (+298,370)
|
|||
|
2020 Q1
|
2.92%
|
$152.25
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.